Technology | Interventional Radiology | August 16, 2019

Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro

U.S. commercial launch of transurethral prostate tissue ablation system combining MRI and ultrasound expected in the fourth quarter of 2019

Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro

August 16, 2019 — Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Tulsa-Pro for ablation of prostate tissue.

Tulsa-Pro is a transurethral prostate tissue ablation system that combines real-time magnetic resonance imaging (MRI) with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue. The Tulsa-Pro system is designed to provide customizable and predictable, incision-free and radiation-free prostate ablation while actively protecting the urethra and rectum with water cooling to preserve men’s functional abilities.

The FDA’s clearance of Tulsa-Pro was based on the company’s TACT pivotal clinical trial, which met all of its primary and secondary efficacy and safety endpoints. TACT enrolled 115 patients across the United States, Canada and Europe with biopsy-proven, organ-confined prostate cancer (67 percent and 33 percent of subjects had NCCN intermediate- and low-risk disease, respectively). All patients received primary treatment of whole-gland prostate ablation with sparing of the urethra and urinary sphincter. TACT demonstrated that the Tulsa-Pro provides safe and effective prostate tissue ablation, with minimal adverse events, significant prostate volume and prostate specific antigen (PSA) reduction, and low rates of residual prostate disease. The favorable safety profile offered by the Tulsa-Pro contrasts with radical prostatectomy and radiation therapy that can leave many men with permanent erectile dysfunction, urinary incontinence and bowel dysfunction. The TACT study also demonstrated a favorable risk-benefit profile in the context of other ablative approaches, including whole-gland high intensity focused ultrasound (HIFU) and cryotherapy.

The FDA label for Tulsa-Pro will allow U.S. surgeons to perform prostate tissue ablation procedures indiscriminate of tissue type, including malignant and benign.

“We are pleased with the FDA’s expeditious review of our application,” said Arun Menawat, Profound’s CEO. “We believe this, combined with the label that the Agency approved for TULSA-PRO®, serves as a testament to our technology’s strong clinical profile.”

Profound Medical CEO Arun Menawat said the company is preparing for the U.S. commercial launch of Tulsa-Pro in the fourth quarter of 2019. 

For more information: www.profoundmedical.com

Related Content

Profound Medical Corp. Announces First Paid Procedure Using TULSA-PRO System

Profound Medical Corp. and Philips Announce First TULSA-PRO Sale in Finland

Related Content

Gadolinium based contrast dye in brain MRI

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | January 17, 2020
January 17, 2020 — Bracco Diagnostics Inc., the U.
Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population

Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population. Chart courtesy of the American Cancer Society

News | Radiation Oncology | January 13, 2020
January 13, 2020 — The cancer death rate declined
Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital.

Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital. Image courtesy of Saarland University/Thorsten Mohr

 

News | Prostate Cancer | January 13, 2020
January 13, 2020 — When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewha
MR Solutions cryogen free preclinical MRI
News | Magnetic Resonance Imaging (MRI) | January 09, 2020
January 9, 2020 — MR Solutions is continuing to expand its support network
Sponsored Content | Videos | Ultrasound Imaging | January 06, 2020
The Arietta 850SE provides facilities with numerous features and functionality to get the most out of a system.
prostate cancer UCL study
News | Prostate Cancer | January 03, 2020
January 3, 2020 — Nearly one in six deaths from...
Videos | MRI Breast | December 26, 2019
Gillian Newstead, M.D., director of global breast imaging and former professor at the University of Chicago, explains